Thomas Ashcom
Cardiovascular Disease · Wichita, KSNPI 1689637027
Payments from drug & device makers
Across 374 payments — averaging $516.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$75K
- Novartis$48K
- AstraZeneca$34K
- Bayer$17K
- Boehringer Ingelheim Pharma GmbH & Co.kg$13K
- Medtronic$2K
- plus $6K from 31 others
What the payments were for
- Travel & lodging$7769%
- Food & beverage$7,76288%
- Education$1732%
- Gifts$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 44 | $74,592 |
| Novartis | 41 | $47,694 |
| AstraZeneca | 33 | $33,517 |
| Bayer | 9 | $16,884 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $13,354 |
| Medtronic(2 entities) | 43 | $1,690 |
| Siemens Medical Solutions USA, Inc. | 5 | $911 |
| Abbott | 19 | $736 |
| Boehringer Ingelheim | 36 | $548 |
| Boehringer Ingelheim International GmbH | 3 | $431 |
| Actelion Pharmaceuticals US, Inc. | 5 | $318 |
| Johnson & Johnson | 9 | $276 |
| Merck | 8 | $266 |
| Pfizer | 15 | $257 |
| E.r. Squibb & Sons, L.L.C. | 44 | $242 |
| Edwards Lifesciences | 1 | $166 |
| Abiomed | 2 | $149 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $144 |
| Amarin Pharma, Inc. | 5 | $127 |
| Novo Nordisk | 6 | $123 |
| Inari Medical, Inc. | 1 | $120 |
| Cvrx, Inc. | 3 | $114 |
| Penumbra, Inc. | 1 | $111 |
| Sanofi-aventis U.S. LLC | 7 | $92 |
| Gilead | 3 | $47 |
| Boston Scientific | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Coala Life Inc | 1 | $35 |
| Astellas Pharma US Inc | 2 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $30 |
| Bardy Diagnostics, Inc. | 3 | $28 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Getinge USA Sales, LLC | 1 | $24 |
| Teleflex LLC | 1 | $20 |
| Heartflow, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Artis zee$714
- Micra$522
- Repatha$362
- FLOWTRIEVER CATHETER, S$239
- Edwards SAPIEN 3 Transcatheter Heart Valve$166
- MitraClip System$146
- Xience V coronary stent system$144
- PRESSUREWIRE$135
- XARELTO$126
- JARDIANCE$125
- WAINUA$125
- Impella$124
- ACUSON Origin Diagnostic Ultrasound System$122
- SYMPLICITY G3$120
- Indigo System$111
- UPTRAVI$102
- OPSUMIT$102
How this compares
$193,236 in reported general payments places this provider in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 942 | $709,343 |
| XareltoRivaroxaban | 399 | $328,282 |
| EntrestoSacubitril/Valsartan | 269 | $235,492 |
| FarxigaDapagliflozin Propanediol | 208 | $161,277 |
| Repatha SureclickEvolocumab | 170 | $112,148 |
| JardianceEmpagliflozin | 138 | $95,514 |
| VerquvoVericiguat | 55 | $42,084 |
| BrilintaTicagrelor | 49 | $30,028 |
| VascepaIcosapent Ethyl | 48 | $25,203 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 975 | $21,451 |
| JanuviaSitagliptin Phosphate | 15 | $13,187 |
| Atorvastatin Calcium | 1,558 | $10,940 |
| CorlanorIvabradine Hcl | 20 | $10,809 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $10,682 |
| DapagliflozinDapagliflozin Propanediol | 16 | $8,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $257 | $709,343942 claims |
| Johnson & JohnsonXarelto | $276 | $328,282399 claims |
| NovartisEntresto | $47,694 | $235,492269 claims |
| AstraZenecaFarxiga, Brilinta | $33,517 | $191,305257 claims |
| Boehringer IngelheimJardiance, Pradaxa | $548 | $99,018155 claims |
| MerckVerquvo, Januvia | $266 | $55,27070 claims |
| AmgenCorlanor | $74,592 | $10,80920 claims |
| Esperion Therapeutics, Inc.Nexlizet | $28 | $10,68211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Aziz MaksoudWichita$847K
- Joseph GalichiaWichita$177K
- Layne ReusserWichita$91K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.